Novartis, Pfizer and Amgen top pharma's lobby spending in eventful Q1

Fierce Pharma ------- Even as Washington politicians are busy on a range of proposals that might impact the drug industry, new data show that pharmaceutical lobbying groups and drugmakers including Pfizer, Amgen and Mylan have been busy as well, boosting their spending in hopes of influencing the way legislation gets written. Compared to 2016’s first quarter, the industry’s top lobby group, PhRMA, increased lobby spending by 34% to $7.98 million in the first three months of this year, according to info from media group Axios. But that paled on a first-quarter percent basis compared to Mylan and Teva, which topped all other pharma players with Q1 increases of 138% and 115%, respectively. To learn more click on the picture below to read the article.